| __timestamp | Bausch Health Companies Inc. | Regeneron Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 2026300000 | 504755000 |
| Thursday, January 1, 2015 | 2682700000 | 838526000 |
| Friday, January 1, 2016 | 2810000000 | 1177697000 |
| Sunday, January 1, 2017 | 2582000000 | 1320433000 |
| Monday, January 1, 2018 | 2473000000 | 1556200000 |
| Tuesday, January 1, 2019 | 2554000000 | 1834800000 |
| Wednesday, January 1, 2020 | 2367000000 | 1346000000 |
| Friday, January 1, 2021 | 2624000000 | 1824900000 |
| Saturday, January 1, 2022 | 2625000000 | 2115900000 |
| Sunday, January 1, 2023 | 2917000000 | 2631300000 |
| Monday, January 1, 2024 | 2954400000 |
Infusing magic into the data realm
In the ever-evolving pharmaceutical industry, effective cost management is crucial for sustaining growth and innovation. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two industry titans: Regeneron Pharmaceuticals, Inc. and Bausch Health Companies Inc., from 2014 to 2023.
Over the past decade, Bausch Health has consistently maintained higher SG&A expenses compared to Regeneron, with a peak in 2023, reaching approximately 2.9 billion USD. This represents a 44% increase from 2014. In contrast, Regeneron has shown a remarkable upward trend, with its SG&A expenses surging by over 420% during the same period, culminating in 2023 with expenses of around 2.6 billion USD.
These trends highlight differing strategic approaches: Bausch's steady expenditure suggests a focus on maintaining market presence, while Regeneron's rapid increase may indicate aggressive expansion and investment in growth initiatives.
Eli Lilly and Company vs Regeneron Pharmaceuticals, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Gilead Sciences, Inc. or Bausch Health Companies Inc.
Who Optimizes SG&A Costs Better? Regeneron Pharmaceuticals, Inc. or Protagonist Therapeutics, Inc.
Comparing SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Mesoblast Limited Trends and Insights
Regeneron Pharmaceuticals, Inc. and Dynavax Technologies Corporation: SG&A Spending Patterns Compared
Alkermes plc vs Bausch Health Companies Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Opthea Limited and Bausch Health Companies Inc.
Who Optimizes SG&A Costs Better? Verona Pharma plc or Bausch Health Companies Inc.
Operational Costs Compared: SG&A Analysis of PTC Therapeutics, Inc. and Bausch Health Companies Inc.
Bausch Health Companies Inc. vs MannKind Corporation: SG&A Expense Trends
Selling, General, and Administrative Costs: Bausch Health Companies Inc. vs Wave Life Sciences Ltd.
Comparing SG&A Expenses: Bausch Health Companies Inc. vs Ligand Pharmaceuticals Incorporated Trends and Insights